glp 1 agonist lilly Drugmaker Eli announced that the FDA approved its daily GLP-1 pill, which will be marketed under the name Foundayo, to treat obesity. ABC News' Youri Benadjaoud reports. https://abcnewslive.visitlink.me/pYGbNh Novel oral GLP-1 receptor agonist

Market analysts anticipate eight or more novel GLP-1-based approvals for chronic weight management over the next four years, as the drug class extends from its metabolic origins into a broader platform for addressing diseases with underlying inflammatory and cardiometabolic components

The overall risk is low

doi: 10.2337/dc24-1972 [DOI] [PMC free article] [PubMed] [Google Scholar] 4.Pan XH, Tan B, Chin YH, et al

2024, doi: 10.2147/JIR.S442106

A Danish study from 2022, which administered exenatide the drug developed from the Gila monster found no broad differences in cravings or drinking reduction between those on the drug and those on a placebo

41 Appendage of the amino acid sequences of either cagrilintide or pramlintide to the C-terminus of semaglutide resulted in significantly diminished potency at the AMYR, with a 2050-fold decrease compared to cagrilintide